{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:06:51Z","timestamp":1758474411239},"reference-count":39,"publisher":"Walter de Gruyter GmbH","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In recent years, L-Dopa treatment has been indicated as an acquired cause of hyperhomocysteinemia (HHcy). The mechanism underlying L-Dopa-related HHcy is the O-methylation of the drug catalyzed by the enzyme catechol-O-methyltransferase (COMT). Folate and cobalamin status also influences the effects of L-Dopa on plasma homocysteine (Hcy) levels. Although clinical correlations of HHcy in Parkinson's disease still remain uncertain, management of elevated plasma Hcy levels has been advocated, due to multiple cytotoxic effects of Hcy on neurons. This review summarizes data available in the literature concerning the two main therapeutic approaches to L-Dopa-related HHcy (use of COMT inhibitors or B vitamins diet supplementation).<\/jats:p><jats:p>Clin Chem Lab Med 2007;45:1607\u201313.<\/jats:p>","DOI":"10.1515\/cclm.2007.337","type":"journal-article","created":{"date-parts":[[2007,10,26]],"date-time":"2007-10-26T13:40:52Z","timestamp":1193406052000},"source":"Crossref","is-referenced-by-count":9,"title":["Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review"],"prefix":"10.1515","volume":"45","author":[{"given":"Stefano","family":"Zoccolella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Iliceto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"deMari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Livrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Lamberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref321","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.WNF.0000220817.94102.95","article-title":"The controversy concerning plasma homocysteine in Parkinson disease patients treated with Levodopa alone or with entacapone : effects of vitamin status","volume":"29","author":"Zesiewicz","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"ref421","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000265412.38632.96","article-title":"Vitamins and entacapone in Levodopa - induced hyperhomocysteinemia : a randomized con - trolled study","volume":"68","author":"Di Rocco","year":"2007","journal-title":"Neurology"},{"key":"ref341","article-title":"Entacapone signifi - cantly decreases elevated plasma homocysteine levels in levodopa - treated Parkinson s disease patients wabstractx","volume":"20","author":"Nissinen","year":"2005","journal-title":"Mov Disord"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(02)00353-2","article-title":"- moto Hypertrophy of IMC of carotid artery in Parkinson s disease is associated with levodopa , homo - cysteine and MTHFR genotype","volume":"207","author":"Nakaso","year":"2003","journal-title":"J Neurol Sci"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00702-004-0262-4","article-title":"Hel - kamaa The COMT inhibitor , entaca - pone , reduces levodopa - induced elevations in plasma homocysteine in healthy adult rats","volume":"112","author":"Nissinen","year":"2005","journal-title":"Neural Trans"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archneur.60.1.59","article-title":"Elevated plasma homocysteine levels in patients treated with Levodopa","volume":"60","author":"Rogers","year":"2003","journal-title":"Arch Neurol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002826-199702000-00007","article-title":"Effect of Dopa and the cat - echol - methyltransferase inhibitor - on sulfur amino acid metabolites in rats","volume":"41","author":"Miller","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000007984","article-title":"van Oppenraaij - tek Elevated plasma levels of homocysteine in Parkinson s disease","volume":"40","author":"Kuhn","year":"1998","journal-title":"Eur Neurol"},{"key":"ref31","first-page":"527","article-title":"Sulfate and cysteine levels in the plasma of patients with Parkinson s disease","volume":"16","author":"Allain","year":"1995","journal-title":"Neurotoxicology"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000219815.83681.f7","article-title":"Vitamins and entacapone in Levo - dopa - induced hyperhomocysteinemia : a randomized controlled study","volume":"66","author":"Postuma","year":"2006","journal-title":"Neurology"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/clinchem\/47.6.1102","article-title":"Pac - chetti Plasma homocysteine and Dopa metabolism in patients with Parkinson s disease","volume":"47","author":"Blandini","year":"2001","journal-title":"Clin Chem"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1212\/WNL.62.1_suppl_1.S72","article-title":"COMT inhibitors in Parkinson s disease Can they prevent and \/ or reverse levodopa - induced motor complications","volume":"62","author":"Olanow","year":"2004","journal-title":"Neurology"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1600-0404.2003.00135.x","article-title":"Levodopa - induced hyperhomocysteinaemia in Parkin - son s disease","volume":"108","author":"Yasui","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"ref381","first-page":"345","article-title":"Decreased rate of coronary restenosis after lowering of plasma homocysteine levels","author":"Schnyder","year":"2001","journal-title":"Engl J Med"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1212\/01.WNL.0000158674.91134.6E","article-title":"Hub - ble The effect of entacapone on homocysteine levels in Parkinson disease","volume":"64","author":"Ostrem","year":"2005","journal-title":"Neurology"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/mds.20253","article-title":"Modest increase in plasma homocys - teine follows Levodopa initiation in Parkinson s disease","volume":"19","author":"Suilleabhain","year":"2004","journal-title":"Mov Disord"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archneur.61.5.633","article-title":"Levodopa elevates homocysteine : is this a problem","volume":"61","author":"Suilleabhain","year":"2004","journal-title":"Arch Neurol"},{"key":"ref301","first-page":"545","article-title":"Effect of Dopa and entacapone on plasma Hcy level in Parkinson s disease Pilot study wabstractx","volume":"21","author":"Nevrly","year":"2006","journal-title":"Mov Disord"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1212\/WNL.55.3.437","article-title":"Plasma homocysteine and MTHFR genotype in levodopa treated patients with PD","volume":"55","author":"Yasui","year":"2000","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0955-2863(97)00110-1","article-title":"The effect of dopa administration and folate deficiency on plasma homocysteine concentrations in rats","volume":"8","author":"Daly","year":"1997","journal-title":"J Nutr Biochem"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncpneuro0527","article-title":"Neurotoxicity of levodopa : treatment - associated homocysteine increase","volume":"3","author":"Muller","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"ref261","first-page":"101","article-title":"Entacapone but not folate prevents dopa induced hyperhomocysteinemia wabstractx","volume":"20","author":"Krause","year":"2005","journal-title":"Mov Disord"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1740-3391-2-1","article-title":"Daily rhythms in plasma levels of homo - cysteine","volume":"2","author":"Lavie","year":"2004","journal-title":"Circadian Rhythms"},{"key":"ref71","first-page":"677","article-title":"Plasma homo - cysteine and MTHFR genotype in levodopa treat - ed patients with PD","volume":"56","author":"Kuhn","year":"2001","journal-title":"Neurology"},{"key":"ref431","article-title":"Vitamins and entacapone in Levo - dopa - induced hyperhomocysteinemia : a randomized controlled study","volume":"68","author":"Postuma","year":"2007","journal-title":"Neurology"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mds.20261","article-title":"- sio de Mari Effects of levo - dopa and COMT inhibitors on plasma homocysteine in PD patients","volume":"20","author":"Lamberti","year":"2005","journal-title":"Mov Disord"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archneur.61.5.657","article-title":"Levodopa associated homocysteine increase and sural axonal neurodegene - ration","volume":"61","author":"Muller","year":"2004","journal-title":"Arch Neurol"},{"key":"ref281","first-page":"131","article-title":"de Mari - berti Plasma homocysteine lev - els in Parkinson s disease : role of antiparkinsonian medications Park Relat","volume":"11","author":"Zoccolella","year":"2005","journal-title":"Disord"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1468-1331.2004.00973.x","article-title":"- dosio de Mari Hyperhomocysteinemia in dopa treated Parkinson s disease patients : effect of cobalamin and folate administration","volume":"12","author":"Lamberti","year":"2005","journal-title":"Eur J Neurol"},{"key":"ref111","first-page":"677","article-title":"polymor - phism , folic acid and hyperhomocysteinemia in levo - dopa treated patients with Parkinson s disease","volume":"64","author":"Woitalla","year":"2004","journal-title":"Neural Transm Suppl"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1073\/pnas.94.11.5923","article-title":"D Emilia DM Neurotoxicity associated with dual actions of homocysteine at the methyl - - aspartate receptor","volume":"94","author":"Lipton","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.1993.03510220049033","article-title":"Vitamin status and intake as primary determinants of homocysteinemia in an elderly population","volume":"270","author":"Selhub","year":"1993","journal-title":"Am Med Assoc"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.WNL.0000137886.74175.5A","article-title":"Homocysteine and levodopa Should Parkinson disease patients receive preventative therapy","volume":"63","author":"Postuma","year":"2004","journal-title":"Neurology"},{"key":"ref101","first-page":"308","article-title":"Decrease of methionine and adenosylmethionine and : Management of homocysteine levels in Dopa treated PD patients Article in press - uncorrected proof increase of homocysteine in treated patients with Par - kinson s disease","volume":"54","author":"Muller","year":"1612","journal-title":"Neurosci Lett"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1161\/01.STR.0000106762.55994.86","article-title":"Folate vitamin and intakes in relation to risk of stroke among men","volume":"6","author":"He","year":"2004","journal-title":"Stroke"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0140-6736(99)01660-8","article-title":"Nigral endothelial dysfunction , homocysteine and Parkinson s disease","volume":"354","author":"Muller","year":"1999","journal-title":"Lancet"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00228-006-0132-0","article-title":"Tolcapone decreases plasma levels of adenosyl homocysteine and homocysteine in treated Parkinson s disease patients","volume":"62","author":"Muller","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"ref291","first-page":"253","article-title":"- terova Reduced plasma homocysteine levels in levodopa \/ entacapone treated Parkinson s dis - ease patients Park Relat","volume":"11","author":"Valkovic","year":"2005","journal-title":"Disord"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neuro.2005.01.008","article-title":"Effects of homocysteine on the dopaminergic system and behav - ior in rodents","volume":"26","author":"Lee","year":"2005","journal-title":"Neurotoxicology"}],"container-title":["Clinical Chemical Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/CCLM.2007.337\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T22:51:40Z","timestamp":1619045500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/CCLM.2007.337\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,1]]},"references-count":39,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1515\/cclm.2007.337","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1,1]]}}}